Results 61 to 70 of about 4,708,479 (153)
6 páginasThis is a pharmacokinetic study of two formulations containing Bosentan 125 mg, in order to compare the bioavailability between the Test product (Bosentan produced by Tecnoquímicas S.A.
Bustamante C., Villarraga EA., Vargas M.
core +1 more source
Non-equivalence of antibiotic generic drugs and risk for intensive care patients [PDF]
Background: The underlying axiom in applying generic drugs is the equivalence of their active ingredient with the (usually more expensive) innovator product, an all-embracing statement with the insidious result that physicians assume that the generic ...
Reshetnykov, Mykhaylo +4 more
core +1 more source
Machine Learning Enables Rapid Prediction of Acid‐Reducing Agent Drug Interactions: A Streamlined Complement to PBPK Modeling. ABSTRACT pH‐dependent drug–drug interactions (DDIs) commonly occur when acid‐reducing agents (ARAs) are co‐administered with weakly basic drugs.
Yuanfang Qin +6 more
wiley +1 more source
4 páginasThis is a pharmacokinetic study of two formulations containing Desvenlafaxine succinate 50 mg extended release. Its objective was to compare the bioavailability between the Test product (Desvenlafaxine ER produced by Tecnoquímicas S.A., Colombia
Villarraga, E., Vargas, M., Vargas, Jba
core +1 more source
Abstract Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome’s set of protein kinases. Currently approved formulations for tofacitinib citrate are immediate release (IR) tablets, modified release (MR) tablets and IR solution.
Kazuko Sagawa +6 more
openaire +2 more sources
ABSTRACT Bridging studies are often waived for orphan diseases such as multiple myeloma (MM) due to challenges in conducting clinical trials in small and heterogeneous populations. However, demographic and regional differences between trial participants and Asian populations may influence drug exposure and response.
Minji Kang +4 more
wiley +1 more source
Osteoarthritis: Epidemiology, Diagnosis, and Treatment
Osteoarthritis (OA) is a multifactorial degenerative joint disease and a leading cause of disability worldwide. This graphical abstract summarizes the epidemiology, diagnostic strategies, and therapeutic approaches of OA. OA development is driven by aging, metabolic dysregulation, and mechanical stress, leading to progressive joint degeneration ...
Qin Ru +7 more
wiley +1 more source
Review Article - Bioequivalence: Issues and perspectives [PDF]
The design, performance and evaluation of bioavailability and bioequivalence have evolved over the last two decades. Bioequivalence (BE) means the absence of a greater-than-allowable difference between the systemic bioavailability of a test product and ...
Rani, Shubha
core +1 more source
4 páginasThis is a pharmacokinetic study of two formulations containing Lurasidone 80 mg, with the aim to compare the Bioavailability between the Test product (Lurasidone made by Laboratorios Lafrancol S.A, Colombia) and the Reference product (Latuda ...
Vargas M., Villarraga EA
core +1 more source

